AssayIndex

AX-2026-041810

Tirzepatide · 30 mg declared · Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. · lot FGP-2605-R1831

MARGINALVERIFIED
Report ID
AX-2026-041810
Compound
Tirzepatide
Compound class
Incretin analogues and co-agonists
Supplier
FGP — Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.
Batch / lot
FGP-2605-R1831
Declared label claim
30mg
Laboratory
Nordanalyt Laboratories
Assay date
10 Jun 2026
Submitted
16 Jun 2026
Quarter
2026-Q2
Submitter
ar.iyer
Sample provenance
Supplier-supplied
Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 35 min gradient, 214 nm97.58% area≥ 97.0PASS
Total impuritiesRP-HPLC, sum of reported peaks2.42% area≤ 3.0PASS
Largest single impurityRP-HPLC — truncated (3-39)0.94% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula4810.4103Da—NOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)4810.4036Da—NOT TESTED
Mass accuracyobserved vs theoretical-1.4ppm± 15PASS
Total peptide contentby difference from the gravimetric mass balance84.43%w/w—NOT TESTED
Target-compound contenttotal peptide content × purity82.39%w/w—NOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen34.34mg30 mg declaredNOT TESTED
Recovered target peptidegross fill × target content28.293mg30 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim94.3%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate6.84%≤ 8.0PASS
Counter-ion (TFA)anion-exchange ion chromatography8.30%≤ 12.0PASS
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.43%—NOT TESTED
Endotoxinkinetic chromogenic LAL0.41EU/mg≤ 5.0PASS
Sterilitymembrane filtration, USP <71>, 14 dNo growth at 14 d—no growthPASS
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intact—white to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear, colourless, no visible particulates—clear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration4.99—2.5 – 8.0PASS
Retention time (observed)RP-HPLC, 35 min gradient22.95min22.91 ± 0.45 (normalised)PASS
Peak asymmetry (10 % height)Ph. Eur. 2.2.461.31—0.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²57,693—≥ 20,000PASS
Resolution to nearest impurityvs [D-Aib13]-diastereomer0.57—no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

01024204730714095 Tirzepatide22.95 min · 97.58 % 21.2224.8427.59 same trace · ×50 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 0510152025303540 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 57,693, and skew follows the reported asymmetry factor of 1.31. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.94 % impurity against a 97.58 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1Tirzepatide — main peak22.954,742,69097.58—
2truncated (3-39)21.2245,6870.94-222.112
3des-Gly deletion (−57 Da)22.2445,2010.93-57.021
4C20 diacid mono-amide24.8417,4970.36+0.984
5[D-Aib13]-diastereomer22.734,8600.100.000
6tirzepatide dimer27.592,9160.06+4810.410
7trifluoroacetyl adduct (+96 Da)24.041,4580.03+95.982
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4810.4103 Da, computed from C225H348N48O68. All ppm figures on this site are against monoisotopic values — see why that matters.

0255075100575775975117513751575 [M+5H]5+963.09[M+4H]4+1203.61[M+6H]6+802.74 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4810.4036 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
7+688.2087688.2078-0.00099.3
6+802.7423802.7412-0.001156.0
5+963.0893963.0880-0.0013100.0
4+1203.60991203.6082-0.001758.5
3+1604.47741604.4751-0.00239.3
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer6.84
Counter-ion (TFA)ion chromatography8.30
Residual solvent + inorganic residueestimated0.43
Total peptide contentby difference84.43
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)98.4897.58divergence +0.78 pp vs batch median
Total impurities (% area)1.522.42
Largest single impurity (% area)0.740.94
Water (%)not stated6.84
Counter-ion (%)not stated8.30
Peptide content (%w/w)not stated84.43
Endotoxin (EU/mg)not stated0.41
Method stated on certificateYES—column, gradient and wavelength given
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Supplier-supplied
Evidentiary weight
Weaker evidence. Read with the caveat below.
Chain of custody
Supplier despatch → laboratory direct (courier, cold pack, 5 d) → assay. Submitter did not handle the vial.
Assay date
10 Jun 2026
Submitted to the index
16 Jun 2026
Laboratory
Nordanalyt Laboratories, Uppsala, Sweden
Method basis
35 min gradient · high-resolution MS
Verification status
VERIFIED
Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot FGP-2605-R1831 n=15

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041801FGP-2605-R1831Janoshik2026-Q297.707.19—Supplier-supplied2MARGINAL
AX-2026-041802FGP-2605-R1831Medutest2026-Q298.076.43—Supplier-supplied2MARGINAL
AX-2026-041803FGP-2605-R1831PeptideMeter2026-Q298.266.01104.9Supplier-supplied2MARGINAL
AX-2026-041804FGP-2605-R1831Janoshik2026-Q297.676.4792.2Buyer-sourced2MARGINAL
AX-2026-041805FGP-2605-R1831PeptideMeter2026-Q297.496.00—Supplier-supplied2MARGINAL
AX-2026-041806FGP-2605-R1831Janoshik2026-Q297.656.22—Supplier-supplied2MARGINAL
AX-2026-041807FGP-2605-R1831Janoshik2026-Q298.116.4796.6Supplier-supplied2MARGINAL
AX-2026-041808FGP-2605-R1831PeptideMeter2026-Q297.955.9988.5Supplier-supplied3MARGINAL
AX-2026-041809FGP-2605-R1831Nordanalyt2026-Q297.486.7397.8Supplier-supplied2MARGINAL
AX-2026-041811FGP-2605-R1831Medutest2026-Q298.096.2189.8Supplier-supplied3MARGINAL
AX-2026-041812FGP-2605-R1831Kestrel2026-Q298.756.88—Supplier-supplied2MARGINAL
AX-2026-041813FGP-2605-R1831PeptideMeter2026-Q297.376.17—Supplier-supplied2MARGINAL
AX-2026-041814FGP-2605-R1831Janoshik2026-Q298.016.1990.1Supplier-supplied2MARGINAL
AX-2026-041815FGP-2605-R1831VendorInvestigate2026-Q296.866.01—Buyer-sourced2FAIL

Cross-sections

Other recent Tirzepatide records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-043106KPKP-2608-D5921PeptideMeter2026-Q398.905.45105.4Supplier-supplied2MARGINAL
AX-2026-041742FGPFGP-2603-L9714Janoshik2026-Q399.372.43105.5Supplier-supplied1MARGINAL
AX-2026-043108KPKP-2608-D5921Janoshik2026-Q399.705.45—Supplier-supplied2MARGINAL
AX-2026-041741FGPFGP-2603-L9714PeptideMeter2026-Q398.622.57—Supplier-supplied1MARGINAL
AX-2026-043100KPKP-2608-D5921VendorInvestigate2026-Q398.275.3194.4Buyer-sourced2MARGINAL
AX-2026-043322CPCCPC-2607-L2552Janoshik2026-Q396.794.8896.1Supplier-supplied2FAIL
AX-2026-043111KPKP-2608-D5921PeptideMeter2026-Q399.715.15—Supplier-supplied2MARGINAL
AX-2026-043321CPCCPC-2607-L2552Kestrel2026-Q397.845.34—Supplier-supplied2MARGINAL
Other recent FGP records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041742TirzepatideFGP-2603-L9714Janoshik2026-Q399.372.43105.5Supplier-supplied1MARGINAL
AX-2026-041767SemaglutideFGP-2602-M1508PeptideMeter2026-Q398.652.54—Supplier-supplied2FAIL
AX-2026-041741TirzepatideFGP-2603-L9714PeptideMeter2026-Q398.622.57—Supplier-supplied1MARGINAL
AX-2026-041772SemaglutideFGP-2602-M1508Janoshik2026-Q399.793.03107.5Supplier-supplied0PASS
AX-2026-041770SemaglutideFGP-2602-M1508VendorInvestigate2026-Q399.331.4890.3Buyer-sourced1MARGINAL
AX-2026-041769SemaglutideFGP-2602-M1508Janoshik2026-Q399.132.5592.9Supplier-supplied1MARGINAL
AX-2026-041768SemaglutideFGP-2602-M1508Janoshik2026-Q398.852.2090.3Supplier-supplied1MARGINAL
AX-2026-041771SemaglutideFGP-2602-M1508Janoshik2026-Q399.412.31—Supplier-supplied0PASS